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ABSTRACT 37 
Background: The effects of oral anticoagulation in chronic kidney disease (CKD) are 38 
uncertain.  39 
Purpose: To evaluate benefits and harms of vitamin K antagonists (VKA) and non-vitamin K 40 
oral anticoagulants (NOAC) in patients with CKD stages 3 to 5, including those with 41 
dialysis-dependent end-stage kidney disease (ESKD). 42 
Data Sources: Medline, EMBASE, and Cochrane databases from inception to February 2019 43 
with English language restriction; bibliographies of reviews; Clinicaltrials.gov (February 25, 44 
2019)  45 
Study selection: Randomized controlled trials evaluating VKA or NOAC in adult CKD 46 
patients for any indication, and reported efficacy and/or bleeding outcomes.  47 
Data Extraction: Two authors independently extracted data, performed risk of bias 48 
assessment, and rated certainty of evidence. 49 
Data Synthesis: Forty-five trials, involving 34,082 participants anticoagulated for atrial 50 
fibrillation ([AF] (eleven trials), venous thromboembolism ([VTE] eleven trials), 51 
thromboprophylaxis (six trials), prevention of dialysis-access thrombosis (eight trials), and 52 
cardiovascular disease other than AF (nine trials) were included. All but the eight trials 53 
involving ESKD patients excluded participants with creatinine clearance <20 mL/min or 54 
estimated glomerular filtration rate <15 mL/min/1.73 m2. In AF, compared with VKA, 55 
NOAC reduced the risks of stroke or systemic embolism (risk ratio 0.79, 95%CI 0.66–0.93; 56 
high certainty evidence), and hemorrhagic stroke (0.48, 0.30–0.76; moderate certainty 57 
evidence). Compared with VKA, NOAC effects on recurrent VTE or VTE-related death were 58 
uncertain (0.72, 0.44–1.17; low certainty evidence). In all trials combined, NOAC reduced 59 
major bleeding risk compared to VKA, though the finding was not statistically significant 60 
(0.75, 0.56–1.01; low certainty evidence). 61 
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Limitation: Scant evidence among patients with advanced CKD stages or ESKD, data 62 
mostly extracted from subgroup analyses of large trials. 63 
Conclusion: In early stages of CKD, NOAC had a benefit-risk profile superior to VKA with 64 
a clear reduction in the risk of stroke or systemic embolism in AF, and reduction in overall 65 
major bleeding risk that was not statistically significant. There is insufficient evidence to 66 
conclude whether patients with advanced CKD stages or ESKD derive benefit from VKA or 67 
NOAC. 68 
Registration: International Prospective Register of Systematic Reviews PROSPERO 2017 69 
CRD42017079709 (December 4, 2017) 70 
Primary Funding Source: None.  71 
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INTRODUCTION 72 
Chronic kidney disease (CKD) is a pro-thrombotic state, associated with substantially 73 
increased risks of arterial and venous thromboembolism (VTE) (1). In addition, atrial 74 
fibrillation is highly prevalent in this population, affecting 18% of patients with CKD (2), and 75 
12-25% of patients with dialysis-dependent end-stage kidney disease (ESKD) (3, 4). The 76 
presence of CKD increases the risks of stroke or systemic embolism, congestive heart failure, 77 
myocardial infarction, and all-cause death among patients with atrial fibrillation (5, 6). 78 
Compared with people with normal kidney function, the risk of VTE is almost two-fold 79 
greater among those with estimated glomerular filtration rate (eGFR) between 15 and 59 80 
mL/min/1.73 m2) (7), and three-fold greater in patients with dialysis-dependent ESKD (8). 81 
VTE in ESKD is also associated with increased risks of bleeding and all-cause death (8). 82 
Other common clinical manifestations of increased thrombotic risk in CKD include acute 83 
coronary syndrome, stroke, peripheral arterial occlusion, and dialysis access thrombosis (1, 84 
9).  85 
Anticoagulant therapy is an important intervention in the prevention of cardiovascular 86 
thrombotic and VTE events. Evidence-based treatment guidelines recommend 87 
anticoagulation for the prevention of stroke in patients with nonvalvular atrial fibrillation and 88 
a CHA2DS2-VASc score ≥2 in men or ≥3 in women (10, 11), VTE in major orthopedic or 89 
non-orthopedic surgical patients or hospitalized acutely ill medical patients (12), and 90 
recurrent VTE in patients with VTE disease (13).  91 
Patients with advanced stages of CKD and ESKD with atrial fibrillation are 92 
prescribed oral anticoagulant therapy less frequently than those with normal kidney function 93 
(3, 14). The use of warfarin in patients on dialysis who have atrial fibrillation varies 94 
considerably, ranging from as low as 2% in Germany to 37% in Canada (3). The low rates of 95 
anticoagulant therapy use in advanced CKD and ESKD may be due to the increased risk of 96 
bleeding, uncertainty regarding potential benefits in this population, warfarin-associated 97 
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calciphylaxis, and warfarin-related nephropathy (15, 16). In CKD, the risk of major bleeding 98 
increases linearly with declining eGFR (17). In patients with dialysis-dependent ESKD, the 99 
bleeding risk is further increased with the incremental use of antithrombotic agents such as 100 
warfarin and antiplatelet agents (18). The exclusion of CKD patients from nearly 90% of 101 
trials evaluating anticoagulant interventions has contributed to uncertainty on the role of 102 
anticoagulant therapy in CKD (19).  103 
The aim of the current systematic review was to evaluate the benefits and harms of 104 
oral anticoagulant (OAC) therapy for a range of clinical indications in patients with CKD 105 
stages 3 to 5, including those receiving dialysis. 106 
  107 
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METHODS 108 
The systematic review and meta-analysis was conducted according to the Preferred 109 
Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) statement (20). The 110 
protocol of this review was prospectively registered in the International Prospective Register 111 
of Systematic Reviews (PROSPERO; December 4, 2017) and can be accessed at: 112 
https://www.crd.york.ac.uk/prospero/display_record.php?RecordID=79709  113 
Data Sources and Searches 114 
Relevant studies were identified by searching Medline (inception to February 2019), 115 
Embase (inception to February 2019), and the Cochrane Central Register of Controlled Trials 116 
(January 2019) with English language restriction using search strategy described in 117 
Appendix Table 1. In addition, reference lists of relevant systematic reviews were searched. 118 
Online trial registry Clinicaltrials.gov was searched (February 25, 2019) using the following 119 
terms: chronic kidney disease, renal dialysis, atrial fibrillation and anticoagulation. 120 
Study Selection and Outcomes 121 
Studies were eligible for inclusion if they (i) were randomized controlled trials; (ii) 122 
included adults with CKD (creatinine clearance [CrCl] <60 mL/min or eGFR <60 123 
mL/min/1.73 m2), or dialysis-dependent ESKD; (iii) compared vitamin K antagonist (VKA) 124 
or non-vitamin K oral anticoagulant (NOAC) to another oral anticoagulant, placebo, low-125 
molecular weight heparin (LMWH), aspirin, or no study medication; and (iv) reported 126 
efficacy and/or bleeding outcomes. All indications for anticoagulation were eligible for 127 
inclusion. Two authors (J.T.H. and B.L.N.) independently reviewed each title and abstract, 128 
and performed full-text review of shortlisted studies. Disagreements about study eligibility 129 
were resolved via consultation with two other authors (S.V.B. and V.P.). If multiple 130 
secondary publications of the same trial were identified, the publication with the most 131 
complete data was used and additional data from secondary sources were extracted. 132 
Incomplete, or unpublished data from trials were requested from the investigators. 133 
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The outcomes of this systematic review were: stroke or systemic embolism in atrial 134 
fibrillation, non-hemorrhagic stroke, hemorrhagic stroke, all-cause or cardiovascular death, 135 
VTE or VTE-related death, myocardial infarction, composite cardiovascular events 136 
(cardiovascular or all-cause death, nonfatal myocardial infarction, or stroke), dialysis access 137 
thrombotic events, major bleeding, major or non-major clinically relevant bleeding, and 138 
intracranial hemorrhage.  139 
Data Extraction and Quality Assessment 140 
Data extraction was carried out independently by two authors (J.T.H. and B.L.N.). 141 
Disagreements were resolved via consultation with two other authors (S.V.B. and V.P.). The 142 
following data were extracted using a standardized form: patient demographic details, study 143 
design and conduct, indication for anticoagulation, dose of drug, non-randomized co-144 
interventions, follow-up duration, and outcome and bleeding events. The methodological 145 
quality of each study included was assessed at the outcome level independently by two 146 
authors (J.T.H. and B.L.N.) using the risk of bias assessment tool developed by the Cochrane 147 
Bias Methods Group (21).  148 
Data Synthesis and Analysis 149 
The results were expressed as risk ratios (RR) with 95% confidence intervals (CI). A 150 
treatment arm continuity correction was used if there were zero events in one arm in a trial. 151 
For trials with three arms comparing two different doses of NOAC with VKA, similar to a 152 
previous meta-analysis (22), data from only the high dose NOAC arm were used for the main 153 
analyses to avoid potentially uninterpretable results by merging of the benefits and harms of 154 
different doses. Additional analyses were conducted by combining data from both high and 155 
low dose arms of NOAC. Summary estimates were obtained by random-effects model using 156 
the Paule-Mandel method (23). If data on the number of events and participants were not 157 
reported, generic inverse variance meta-analysis was performed by calculating log hazard 158 
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ratio and its standard error from the reported hazard ratio and respective CI. Evidence of 159 
statistical heterogeneity across the studies was estimated using the I² test. I² values of 25%, 160 
50%, and 75% were considered to correspond to low, moderate, and high levels of 161 
heterogeneity (24). Statistical analyses were performed using Stata/MP, version 15.1 162 
(StataCorp College Station, Texas), and R statistical software, version 3.5.3 (R Foundation 163 
for Statistical Computing, Vienna, Austria).  164 
Certainty in the evidence was summarized using the Grading of Recommendations 165 
Assessment, Development and Evaluation (GRADE) approach, considering the following 166 
domains: (1) within-study risk of bias, (2) indirectness of evidence, (3) unexplained 167 
heterogeneity or inconsistency of results, and (4) imprecision of results by three authors 168 
(J.T.H., B.L.N., and L.P.C.) and disagreements were resolved via consultation with two other 169 
authors (S.V.B. and M.J.) (25). Because all meta-analyses involved fewer than 10 trials, 170 
small study effects (publication bias) was not assessed and publication bias was not included 171 
in rating certainty of evidence (26). 172 
Role of the Funding Source 173 
There was no funding source for this study. 174 
  175 
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RESULTS 176 
Selection and Description of Studies 177 
Forty-five trials involving 34,082 participants (median sample size 276 [range 10-178 
4,168], median follow-up 12 [range 1-36] months) evaluating VKA or NOAC were included 179 
in the systematic review (Figure 1). Of these trials, eight included 685 participants with 180 
dialysis-dependent ESKD (median sample size 91 [range 18-174], median follow-up 12 181 
[range 3-36] months) evaluating VKA for the prevention of dialysis access thrombosis in 182 
seven trials and one evaluated the effect of VKA on hemostatic factors. The remaining 37 183 
trials included 33,397 participants with CKD, who were not receiving dialysis (defined as 184 
CrCl 20-60 mL/min, eGFR 15-60 mL/min/1.73 m2, or serum creatinine level ≥1.5 mg/dL; 185 
median sample size 380 [range 10-4,168], median follow-up 12 [range 1-36] months). Eleven 186 
trials included 16,787 participants with atrial fibrillation (median sample size 516 [range 12-187 
4,074], median follow-up 14 [range 3-34] months); eleven trials included 2,975 participants 188 
with acute VTE (median sample size 162 [range 72-657], median follow-up 12 [range 6-36] 189 
months), six trials included 3,908 medically ill or peri-operative patients requiring 190 
anticoagulation for thromboprophylaxis (median sample size 380 [range 42-2,197] median 191 
follow-up 2 [range 1-6] months); and the remaining nine trials included 9,727 participants 192 
with cardiovascular disease other than atrial fibrillation (median sample size 331 [range 72-193 
2197] median follow-up 9 [range 1-36] months). Data from the 37 trials involving patients 194 
with non-dialysis CKD were obtained exclusively from CKD subgroup analyses of large 195 
trials. Details of included trials are described in  Appendix Table 2. 196 
NOAC was compared with VKA (15 trials, 16,495 participants), placebo (ten trials, 197 
11,683 participants), LMWH (five trials, 1,720 participants), and aspirin (four trials, 2,690 198 
participants); and VKA was compared with placebo (four trials, 408 participants), no study 199 
medication (four trials, 277 participants), LMWH (two trials, 293 participants), and aspirin 200 
(one trial, 516 participants). The interventional agents were: rivaroxaban (13 trials), 201 
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dabigatran (eight trials), apixaban (seven trials), edoxaban (five trials), betrixaban (one trial), 202 
fixed-dose [1 or 2 mg] or low-intensity [target international normalized ratio (INR) 1.4-1.9] 203 
warfarin (six trials), and adjusted-dose (target INR 1.5-2.5, or 2-3) warfarin or 204 
acenocoumarol (five trials). 205 
Source of funding was not reported in four trials. Thirty-nine of the remaining 41 206 
(95%) trials were sponsored by pharmaceutical companies. 207 
Risk of bias  208 
Risk of bias assessment at outcome level is described in Appendix Table 3. Random 209 
sequence generation and allocation concealment were reported using low risk methods in 210 
80% of trials reporting the outcomes of stroke or systemic embolism, and major bleeding in 211 
trials involving participants with atrial fibrillation. Random sequence generation and 212 
allocation concealment were reported using low risk methods in all trials reporting the 213 
outcome of VTE or VTE-related death in participants with acute VTE or those requiring 214 
thromboprophylaxis, and major adverse cardiovascular events in participants with 215 
cardiovascular disease other than atrial fibrillation. Trials involving participants with dialysis-216 
dependent ESKD reporting the outcomes of hemodialysis access thrombosis or malfunction, 217 
all-cause death, and major bleeding were generally at high or unclear risk of bias in the 218 
domains of random sequence generation and allocation concealment. 219 
Effects of interventions 220 
Trials involving participants with atrial fibrillation 221 
None of the eleven trials involving participants with atrial fibrillation included 222 
patients with dialysis-dependent ESKD. Anticoagulation was used for the prevention of 223 
stroke or systemic embolism in seven trials, acute coronary syndrome or percutaneous 224 
coronary intervention in two trials, and for periprocedural anticoagulation in participants 225 
undergoing cardioversion, or catheter ablation, in one trial each. No trial tested a treatment 226 
strategy of comparing an OAC to no anticoagulation in atrial fibrillation. Compared with 227 
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VKA, high dose NOAC reduced the risks of stroke or systemic embolism (RR 0.79, 95% CI 228 
0.66–0.93), hemorrhagic stroke (RR 0.48, 95% CI 0.30–0.76), and all-cause death (RR 0.88, 229 
95% CI 0.78–0.99); and had no clear effect on non-hemorrhagic stroke though confidence 230 
bounds were wide (RR 1.04, 95% CI 0.83–1.30) (Figure 2, Appendix Figures 1 to 4). 231 
Compared with aspirin, any OAC (VKA or NOAC) reduced the risk of stroke or systemic 232 
embolism (RR 0.30, 95% CI 0.19–0.48). Compared with VKA, high dose NOAC reduced the 233 
risk of major bleeding (RR 0.80, 95% CI 0.61–1.04), although this finding was not 234 
statistically significant (Appendix Figure 5). Compared to VKA, the effect of high dose 235 
NOAC on the risk of major or non-major clinically relevant bleeding was uncertain (RR 0.97, 236 
95% CI 0.76–1.23) (Appendix Figure 6). Additional analyses after the inclusion of both 237 
high and low doses of NOAC showed that, compared with VKA, NOAC reduced the risks of 238 
stroke or systemic embolism (RR 0.87, 95% CI 0.74–1.02), and major bleeding (RR 0.74, 239 
95% CI 0.55–1.00), though these findings were not statistically significant as their respective 240 
upper limits of confidence intervals crossed 1(Appendix Figures 1 and 5). 241 
Trials involving participants with acute VTE  242 
NOAC reduced the risk of recurrent VTE or VTE-related death when compared with 243 
placebo (RR 0.14, 95% CI 0.04–0.48); but had an uncertain effect when compared with VKA 244 
(RR 0.72, 95% CI 0.44–1.17) (Figure 3, Appendix Figure 7). There was no difference in the 245 
risk of recurrent VTE or VTE-related death between any OAC and LMWH (RR 2.10, 95% 246 
CI 0.72–6.15) (Appendix Figure 7). None of the NOAC trials reported data on all-cause 247 
death. There was no difference in the risk of all-cause death between VKA and LMWH (RR 248 
1.01, 95% CI 0.79–1.31). There were no differences in the risk of major bleeding between 249 
NOAC and VKA (RR 0.54, 95% CI 0.21–1.43), VKA and LMWH (RR 1.03, 95% CI 0.43–250 
2.51), and any OAC and LMWH (RR 1.24, 95% CI 0.54–2.88) (Appendix Figure 8). There 251 
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was no difference in the risk of major or non-major clinically relevant bleeding between 252 
NOAC and VKA (RR 0.84, 95% CI 0.63–1.11) (Appendix Figure 9).  253 
Trials involving participants requiring anticoagulation for thromboprophylaxis 254 
There were no clear differences between NOAC and LMWH in the risks of VTE or 255 
VTE-related death (RR 0.85, 95% CI 0.40–1.83), major bleeding (RR 3.72, 95% CI 0.79–256 
17.54), and major or non-major clinically relevant bleeding ( RR 1.09, 95% CI 0.64–1.85) 257 
(Appendix Figure 10). There was no difference in the risk of VTE or VTE-related death (RR 258 
0.98, 95% CI 0.53–1.82) between NOAC and placebo. 259 
Trials involving participants with dialysis-dependent ESKD 260 
None of the eight trials involving participants with dialysis-dependent ESKD 261 
evaluated NOAC (Appendix Figure 11). There was no clear difference in the risk of dialysis 262 
access thrombosis or catheter malfunction between fixed-dose/low-intensity warfarin and 263 
placebo/no study medication (RR 1.04, 95% CI 0.85–1.28) (Appendix Figure 12). 264 
Compared with no study medication, adjusted-dose warfarin reduced the risk of dialysis 265 
access thrombosis or catheter malfunction (RR 0.28, 95% CI 0.16–0.47) (Appendix Figure 266 
12). Compared with placebo or no study medication, the effect of fixed-dose or low-intensity 267 
warfarin on all-cause death (RR 0.65, 95% CI 0.34–1.24), and major bleeding (RR 2.66, 95% 268 
CI 0.39–18.19) were uncertain (Appendix Figures 13 and 14).  269 
Participants with cardiovascular disease other than atrial fibrillation 270 
Compared with placebo, NOAC reduced the risk of major adverse cardiovascular 271 
events (defined as a composite of cardiovascular or all-cause death, non-fatal myocardial 272 
infarction or stroke), though this finding was not statistically significant as the upper limit of 273 
confidence intervals crossed 1 (RR 0.88, 95% CI 0.75–1.04) (Appendix Figures 15 and 16). 274 
In a single trial involving 4,168 participants with stable coronary or peripheral arterial 275 
disease, the risk of major adverse cardiovascular events with low dose NOAC was lower than 276 
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placebo (RR 0.77, 95% CI 0.62–0.95). Compared with placebo, NOAC significantly 277 
increased the risk of major bleeding (2.18, 95% CI 1.10–4.32) (Appendix Figure 17). 278 
Additional analyses with the inclusion of trials comparing only the low dose NOAC with 279 
placebo showed that NOAC reduced the risk of major adverse cardiovascular events (RR 280 
0.89, 95% CI 0.77–1.04) although the upper limit of confidence intervals crossed 1, with no 281 
difference in major bleeding risk (RR 2.29, 95% CI 0.57–9.18) (Appendix Figures 16 and 282 
17).  283 
Bleeding outcomes from all trials combined 284 
Compared with VKA, high dose NOAC reduced the risk of major bleeding (RR 0.75, 285 
95% CI 0.56–1.01), though this finding was not statistically significant as the upper limit of 286 
confidence intervals crossed 1 (Figure 4, Appendix Figure 18). There was no significant 287 
interaction of major bleeding risk by indication for anticoagulation (p=0.84). There was no 288 
clear difference in the risk of major or non-major clinically relevant bleeding (RR 0.95, 95% 289 
CI 0.83–1.07) between the NOAC and VKA groups (Appendix Figure 19). Compared with 290 
VKA, high dose NOAC reduced the risk of intracranial hemorrhage (RR 0.49, 95% CI 0.30–291 
0.80) (Appendix Figure 20). Compared with placebo, NOAC increased the risks of major 292 
bleeding (RR 2.27, 95% CI 1.21–4.26), and major or non-major clinically relevant bleeding 293 
(RR 4.03, 95% CI 1.62–10.03). Compared to LMWH, NOAC increased the risk of major 294 
bleeding (RR 3.67, 95% CI 1.05–12.89), but not major or non-major clinically relevant 295 
bleeding (RR 1.09, 95% CI 0.64–1.85). Additional analysis after the inclusion of high and 296 
low doses of NOAC showed clear reduction in major bleeding risk with NOAC compared 297 
with VKA (RR 0.71, 95% CI 0.52–0.96) (Appendix Figure 18). 298 
 299 
  300 
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DISCUSSION 301 
This review provides a comprehensive overview of the available data describing the 302 
effects of anticoagulation for people with kidney disease and a range of co-morbidities or 303 
other risk factors. It identifies some clear findings that can be used to guide treatment 304 
decisions, but also a number of areas where the available data are inadequate and further 305 
studies are urgently required.  A key finding is that in patients with atrial fibrillation and early 306 
stage CKD, NOAC were superior to VKA, with 21%, 52% and 51% relative risk reductions 307 
in stroke or systemic embolism, hemorrhagic stroke and intracranial hemorrhage, 308 
respectively. However, NOAC did not reduce the risk of non-hemorrhagic stroke in atrial 309 
fibrillation. In AF, NOAC reduced the risk of major bleeding, though this finding was not 310 
statistically significant. Compared with placebo, NOAC reduced the risk of recurrent VTE or 311 
VTE-related death in patients with CKD receiving acute VTE treatment; but when compared 312 
with VKA, this effect was uncertain. These data suggest that NOAC may be a reasonable 313 
option in people with CKD who develop VTE, but further data would be helpful. In all trials 314 
combined, compared with VKA, high dose NOAC reduced the risk of major bleeding, though 315 
this result was not statistically significant. In contrast, for people with advanced stages of 316 
CKD (CrCl <25 mL/min), including dialysis-dependent ESKD, there were no data available 317 
regarding the effects of VKA or NOAC on the prevention of stroke or systemic embolism in 318 
atrial fibrillation, or on VTE and VTE-related death.  319 
Although the rates of ischemic and hemorrhagic stroke, and intracranial hemorrhage 320 
were not reported in all trials involving participants with atrial fibrillation, it is possible that 321 
the benefit of reduced stroke or systemic embolism with NOAC was mainly driven by a 322 
reduction in hemorrhagic stroke. A similar finding was reported in the previously reported 323 
systematic review of four randomized trials comparing NOAC with VKA (22). The excess 324 
burden of atrial fibrillation, cardiovascular thrombotic events and VTE in patients with 325 
advanced CKD contributes to their poor survival (5, 6, 8). Given the greater rates of  arterial 326 
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and venous thrombotic in patients with advanced CKD than those with normal kidney 327 
function, the absolute risk reduction with anticoagulation treatment in this population may be 328 
greater, but this systematic review highlights the absence of evidence in patients with 329 
advanced stages of CKD and ESKD, specifically for the prevention of stroke or systemic 330 
embolism in atrial fibrillation, and recurrent VTE or VTE-related death. The potential benefit 331 
of anticoagulation treatment needs to be balanced against the risk of bleeding in this 332 
population. The rates of major bleeding with apixaban and warfarin in patients with 333 
hemodialysis-dependent ESKD (19.7 and 22.9 per 100 person-years, respectively) (27) are 334 
substantially greater than those with normal or mildly decreased kidney function (2.13 and 335 
3.09 per 100 person-years, respectively) (28). Furthermore, 60-75% of patients with ESKD 336 
discontinue oral anticoagulation within one year, possibly due to bleeding (27, 29). Despite 337 
the absence of specific evidence, current guidelines suggest warfarin with target INR 2.0-3.0 338 
or apixaban (recommendation class: IIa, evidence level: B-NR) (11) and time in therapeutic 339 
range >65-70% (ungraded consensus-based statements) (10) in patients CrCl <15 mL/min or 340 
dialysis-dependent ESKD with a CHA2DS2-VASc score ≥2 in men or ≥3 in women (11). The 341 
lack of evidence-based guidelines strongly suggests that adequately-powered randomized 342 
trials are required to address the unmet need in this population. 343 
 Leveraging their favourable benefit-harm profile, NOAC are now being evaluated for 344 
new cardiovascular indications. In early stage CKD, although NOAC did not reduce major 345 
cardiovascular events after acute coronary syndrome, the combination of low dose 346 
rivaroxaban and aspirin was beneficial for this primary outcome in patients with stable 347 
coronary or peripheral arterial disease in a single trial (30). A dose of rivaroxaban far below 348 
that required for full anticoagulation may be particularly valuable in patients with advanced 349 
CKD and ESKD, who also have an elevated bleeding risk. However, the exclusion of patients 350 
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with eGFR <15 mL/min/1.73 m2 in this trial mandates the testing of this strategy in 351 
randomized trials specifically in patients with advanced CKD and ESKD.  352 
In contrast to the other recent systematic reviews identified by searching Medline to 353 
February 2019, this systematic review demonstrates superiority of NOAC over VKA in 354 
reducing the risk of stroke or systemic embolism in atrial fibrillation (31, 32). Furthermore, 355 
the broad scope of clinical settings of the present review allows a more comprehensive 356 
understanding of effects. Other strengths of this systematic review include inclusion of a 357 
large number of participants, robust evaluation of efficacy and bleeding outcomes, and use of 358 
the GRADE approach to assess the body of evidence. These strengths should be balanced 359 
against its limitations, which are largely due to the limitations of the underlying literature. 360 
These include exclusion of patients with dialysis-dependent ESKD and advanced non-361 
dialysis CKD, limited information on demographic characteristics of the CKD subgroup, 362 
under-reporting of organ-specific bleeding data (especially gastrointestinal bleeding), lack of 363 
individual patient data and suboptimal methodological quality of trials involving participants 364 
with dialysis-dependent ESKD. Data on patients with CKD from trials of NOAC were 365 
obtained exclusively from subgroup analyses of large trials. The current review was not 366 
designed to assess differences between individual NOAC.  367 
There are two ongoing trials comparing apixaban to VKA in participants with 368 
hemodialysis-dependent ESKD and atrial fibrillation (RENAL-AF trial: NCT02942407 and 369 
AXADIA trial: NCT02933697) (33). Another ongoing trial will compare VKA to no oral 370 
anticoagulation in participants with hemodialysis-dependent ESKD and atrial fibrillation 371 
(AVKDIAL: NCT02886962). Future trials should include not only participants with dialysis-372 
dependent ESKD but also those with creatinine clearance <25 mL/min. Since no trial has 373 
evaluated a treatment strategy for comparing an OAC to no anticoagulation in atrial 374 
fibrillation, future trials should compare NOAC to placebo.  375 
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In summary, this systematic review demonstrates that NOAC had a benefit-risk 376 
profile superior to VKA in people with early stages of CKD, with significant reductions in 377 
stroke or systemic embolism and hemorrhagic stroke in atrial fibrillation, and also reduction 378 
in overall major bleeding risk in all trials combined that was not statistically significant, 379 
suggesting that these individuals will derive similar or greater benefit than those who do not 380 
have CKD. However, there is insufficient evidence to recommend widespread use of VKA or 381 
NOAC to improve clinical outcomes in patients with advanced CKD and dialysis-dependent 382 
ESKD. Adequately-powered randomized trials are required to evaluate the benefits and 383 
harms of anticoagulant therapy in this patient population. 384 
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FIGURE LEGENDS 592 
Figure 1. PRISMA flow diagram showing selection of studies 593 
PRISMA flow diagram showing selection of studies. 594 
Abbreviations: CAD, coronary artery disease; ESKD, end-stage kidney disease; PAD: 595 
peripheral artery disease; RCT, randomized controlled trial; VTE, venous thromboembolism. 596 
Figure 2. Summary of treatment effects in trials involving participants with atrial 597 
fibrillation 598 
Forest plot showing treatment effects in trials involving participants with atrial fibrillation on 599 
stroke or systemic embolism, non-hemorrhagic stroke, hemorrhagic stroke, myocardial 600 
infarction, all-cause death, and bleeding outcomes. 601 
Abbreviations: ASA, aspirin; CI, confidence intervals; GRADE, Grading of 602 
Recommendations Assessment, Development and Evaluation; NOAC, non-vitamin K oral 603 
anticoagulants; OAC, oral anticoagulants; RR, risk ratio; VKA, vitamin K antagonists.  604 
Figure 3. Summary of treatment effects in trials involving participants with acute VTE  605 
Forest plot showing treatment effects in trials involving participants with acute VTE on 606 
recurrent VTE or VTE-related death, all-cause death, and bleeding outcomes. 607 
Abbreviations: ASA, aspirin; CI, confidence intervals; GRADE, Grading of 608 
Recommendations Assessment, Development and Evaluation; LMWH, low molecular weight 609 
heparin; NOAC, non-vitamin K oral anticoagulants; OAC, oral anticoagulants; RR, risk ratio; 610 
VKA, vitamin K antagonists; VTE, venous thromboembolism.  611 
Figure 4. Summary of treatment effects on bleeding outcomes in all trials combined 612 
Forest plot showing treatment effects in all trials combined on major bleeding, major or non-613 
major clinically relevant bleeding, and intracranial hemorrhage. 614 
* The number of events were not reported in one trial; hence generic inverse variance meta-615 
analysis was performed. 616 
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Abbreviations: ASA, aspirin; CI, confidence intervals; GRADE, Grading of 617 
Recommendations Assessment, Development and Evaluation; LMWH, low molecular weight 618 
heparin; NOAC, non-vitamin K oral anticoagulants; RR, risk ratio; VKA, vitamin K 619 
antagonists.  620 




